Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Ocugen (OCGN) received provisional approval and priority designation in the Bahamas for its experimental gene therapy, OCU400, aimed at treating retinitis pigmentosa. This marks a significant step in the company's global expansion efforts, with plans to treat the first patient in the Bahamas within 90 days. Ocugen also has other late-stage eye-disease programs and is pursuing commercialization opportunities in various international markets.